CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

BioMarin Q3 2026 net loss more than triples to USD 123 million

By Public Technologies
  • BioMarin's third-quarter 2026 GAAP net loss more than tripled to $123 million year over year, primarily driven by Amicus acquisition costs.
  • Total revenues climbed 32% to $1.02 billion, primarily driven by acquired therapies and VIMIZIM growth.
  • The FDA set a May 30, 2027 target action date for VOXZOGO's potential expansion into hypochondroplasia.
  • Full-year 2026 total revenues guidance fell to $3.8 billion–$3.9 billion, reflecting uncertainty over international order timing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611021603PR_NEWS_USPR_____SF86326) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.